Serum positive cagA in patients with non-ulcer dyspepsia and peptic ulcer disease from two centers in different regions of Turkey

AIM: To investigate and compare frequencies of serum positive cagA in patients from two separate regions of Turkey who were grouped according to the presence of peptic ulcer disease or non-ulcer dyspepsia. METHODS: One hundred and eighty Helicobacter pylori-positive patients with peptic ulcer disease or non-ulcer dyspepsia were included in the study. One hundred and fourteen patients had non-ulcer dyspepsia and 66 had peptic ulcer disease (32 with gastric ulcers and/or erosions and 34 with duodenal ulcers). Each patient was tested for serum antibody to H. pylori cagA protein by enzyme immunoassay. RESULTS: The total frequency of serum positive cagA in the study group was 97.2 %. The rates in the patients with peptic ulcers and in those with non-ulcer dyspepsia were 100 % and 95.6 %, respectively. These results were similar to those reported in Asian studies, but higher than those that have been noted in other studies from Turkey and Western countries. CONCLUSION: The high rates of serum positive cagA in these patients with peptic ulcer disease and non-ulcer dyspepsia were similar to results reported in Asia. The fact that there was high seroum prevalence regardless of ulcer status suggests that factors other than cagA might be responsible for ulceration or other types of severe pathology in H. pylori-positive individuals.     

葡萄糖耐量减低患者微血管并发症临床研究

目的:探讨葡萄糖耐量减低(IGT)患者微血管并发症的发生率。方法:以男性IGT106例患者为研究组,同时选择糖代谢正常的健康人100例为对照组,观察两组中眼底病变、微量白蛋白尿、中国勃起功能问卷调查(CIEF5)的积分、血脂、血压及体重指数(BMI)资料。结果:与正常对照组比较,IGT组微血管并发症发生率显著增加(P均<0.01),且两组间在血脂、血压及BMI等指标方面差异显著(P<0.05);多元回归分析表明微血管并发症与IGT有显著相关性。结论:男性IGT患者可发生与糖尿病患者同样的微血管并发症,其微血管并发症发生的危险因素包括脂质代谢异常,高血压及肥胖,提示控制糖代谢异常对防治糖尿病微血管并发症具有重要意义。     

炎症性肠病疾病活动程度与血小板参数的相关性分析

炎症性肠病（IBD）是病因未明的肠道非特异性炎症，包括溃疡性结肠炎（UC）和克罗恩病（CD），本研究对血小板参数与IBD的活动性是否关联作临床研究分析。     

病毒性肝炎——总论

病毒性肝炎中医治验介绍；肝病患血清肉碱水平的临床研究；生物电阻抗技术在肝病病人人体成分测量中的应用（综述）；病毒性肝炎患凝血因子、抗凝和纤溶指标的研究；肝病伴糖代谢异常患的临床分析；[编按]     

动态长程晚电位监测判断急性心肌梗死再灌注的临床研究

心室晚电位（VLP）是目前公认的估计心室延迟除极活动非常有价值的无创诊断工具。虽然它的发生需要心肌局部一定的物质基础,但近年来人们发现,心肌梗死急性期（24 h内）心肌局部机化、纤维化形成以前的电不稳定时期,晚电位常发生明显的动态变化,其与冠状动脉再通之间的关系尚不肯定。本组应用数字化动态心电图记录仪（北冷公司,世纪3000）对心肌梗死急性期的患者进行24 h监测,以了解其病理生理基础与恢复期患者的病理生理基础有何异同以及急性期晚电位情况与冠状动脉再通之间的关系等。     

生长激素受体（GHR）与肿瘤的临床研究进展

恶性肿瘤病人往往伴有营养不良，术后应用人重组生长激素(rhGH)能明显增加蛋白合成，改善机体免疫功能、降低应激反应以及减少并发症的发生，因而已逐渐在外科术后病人中广泛使用。但是，由于术后体内肿瘤细胞的残留不可避免，使用rhGH是否会刺激肿瘤细胞生长?围手术期使用是否安全?目前学术界尚无共识。由于rhGH作用于细胞生长激素受体(GHR)来发挥作用，所以现将GHR在肿瘤组织中的表达情况以GH—GHR—IGFs轴与肿瘤的关系的有关研究综述加下．     

《中华口腔医学研究杂志(电子版)》“快速通道”稿件要求

本刊对重大研究成果,将使用"快速通道",在最快时间内发表。稿件要求:(1)凡内容涉及重大创新和国内首创,达到或超过国内或国际先进水平的基础和临床研究的论文,均可申请进入"快速通道";(2)作者本人提出进入"快速通道"申请;(3)提供国内外数据库的查新报告;     

微卡辅助治疗耐多药肺结核的临床研究

目的探讨评价微卡（母牛分枝杆菌菌苗）治疗耐多药肺结核的疗效.方法 60例耐多药肺结核患者按入院先后顺序分为微卡加化疗组即治疗组,与单纯化疗组即对照组.化疗方案均为3PaL2AKZThV/15PaL2ZThV.治疗组为病人头3个月每15 d肌注微卡（22.5μg）,随后的3个月每月肌注1次微卡.观察2组治疗后肺部病灶吸收情况、痰菌阴转情况、症状改善情况、免疫功能变化情况.结果治疗组与对照组3个月时痰菌阴转率分别为56.6%和26.6%,18个月时为93.3%和73.3%有显著差异（P＜0.05）;X线吸收率及空洞缩小、闭合率均有明显差异P＜0.05;CD4^＋、CD4^＋/CD8^＋9个月时治疗组与同组治疗前及对照组均有显著差异P＜0.05.结论微卡能调节免疫功能,提高痰菌阴转率,有助于病灶吸收空洞闭合,可作为耐多药肺结核化疗的辅助治疗.     

Portal vein thrombosis： Etiology and clinical outcome of cirrhosis and malignancy-related non-cirrhotic, non-tumoral extrahepatic portal venous obstruction

The etiology and pathogenesis of portal vein thrombosis are unclear. Portal venous thrombosis presentation differs in cirrhotic and tumor-related versus non-cirrhotic and non-tumoral extrahepatic portal venous obstruction (EHPVO). Non-cirrhotic and non-tumoral EHPVO patients are young and present with well tolerated bleeding.Cirrhosis and tumor-related portal vein thrombosis patients are older and have a grim prognosis. Among the 118 patients with portal vein thrombosis, 15.3% had cirrhosis, 42.4% had liver malignancy (primary or metastatic), 6% had pancreatitis (acute or chronic), 5% had hypercoagulable state and 31.3% had idiopathy,12% had hypercoagulable state in the EHPVO group.     

吡格列酮的临床研究进展

噻唑烷二酮类药物（TZD）是一类新型胰岛素增敏剂，通过激动PPARγ改善胰岛素抵抗，纠正相应代谢紊乱。目前主要包括吡格列酮，罗格列酮等。吡格列酮于80年代中期由日本Takeda公司和美国UpJohn公司研究开发，2001年在我国批准生产。近年除在糖尿病领域广泛应用外，还被试用炎症性疾病、肿瘤等方面。现就近年来有关该药的临床研究进展作一综述。